中文版Home
 
2016-11 Handa Pharmaceuticals. Inc. received the “Public Issuance” approval from Taiwan authorities on November 23th 2016. Stock ticker is 6620
2016-11 Handa Pharmaceuticals Announces Endo Begins Shipping Generic Version of AstraZeneca’s SEROQUEL XR®
2016-06 Officially stationed in Southern Taiwan Science Park.
2016-05 Began operations under the new name of Handa Pharmaceuticals, Inc.
2016-02 Completed acquisition of US subsidiary Handa Pharmaceuticals, LLC., and 100% hold of affiliate company Hangzhou Handa Pharmaceutical Technology Co. Ltd. in China.
2015-08 MOST Science Park Commission approved Pharmira Laboratories, Inc. for entrance to the Southern Taiwan Science Park.
2015-04 MOEA Approval as a Biotech & New Pharmaceutical Company.
2014-05 Established the Tainan R&D Center.
2014-05 Taipei City Government approved the establishment of Pharmira Laboratories, Inc., with founding equity of NTD$55 million.
 
PREV    /      1      /   NEXT
 

ADD:3F.-1,3F-2, No.23, Nanke 3rd Rd., Xinshi Dist., Tainan City 74147, Taiwan      TEL:+886-6-5057508      FAX:+886-6-5057502     EMAIL:service@handapharma.com.tw

©Handa Pharmaceuticals,Inc  
Designed by ETAN